FRANKFURT\/BERLIN (Reuters) – Bayer stood by its peak sales estimate for clot prevention drug Xarelto after the pill disappointed in a late-stage trial to test prevention of repeat strokes. <\/p>\n
The Phase III study had been halted early after the drug showed no efficacy improvements over low-dose aspirin, Bayer said in a statement late on Thursday. <\/p>\n
The German drugmaker last year raised its annual peak sales estimate for Xarelto to more than 5 billion euros ($5.3 billion). <\/p>\n
The study was evaluating the efficacy and safety of Xarelto, also known as rivaroxaban, for the secondary prevention of stroke and systemic embolism in patients with a recent embolic stroke of undetermined source. <\/p>\n
\u201cWhile bleeding rates were low overall, an increase in bleeding was observed in the rivaroxaban arm compared to the low dose aspirin arm,\u201d Bayer said in its statement. <\/p>\n
The drug is already approved for a number of cardiovascular conditions and prevention of strokes caused by a type of irregular heart beat common among the elderly is the main profit driver. <\/p>\n
Earlier this year, a successful trial on the prevention of potentially deadly strokes and heart attacks in patients with severe atherosclerosis raised the prospect of billions more in sales. <\/p>\n
Xarelto was jointly developed by Bayer and Johnson Johnson, which owns the U.S. rights to the drug. <\/p>\n
Bayer said the trial has no bearing on the positive benefits of Xarelto for other uses for which it is currently licensed. <\/p>\n
Reporting by Victoria Bryan and Ludwig Burger; Editing by Muralikumar Anantharaman and Keith Weir<\/p>\n","protected":false},"excerpt":{"rendered":"
FRANKFURT\/BERLIN (Reuters) – Bayer stood by its peak sales estimate for clot prevention drug Xarelto after the pill disappointed in a late-stage trial to test prevention of repeat strokes. The Phase III study had been halted early after the drug showed no efficacy improvements over low-dose aspirin, Bayer said in a statement late on Thursday. Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-203522","post","type-post","status-publish","format-standard","hentry"],"_links":{"self":[{"href":"http:\/\/healthmedicinet.com\/i\/wp-json\/wp\/v2\/posts\/203522","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/healthmedicinet.com\/i\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/healthmedicinet.com\/i\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/healthmedicinet.com\/i\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/healthmedicinet.com\/i\/wp-json\/wp\/v2\/comments?post=203522"}],"version-history":[{"count":0,"href":"http:\/\/healthmedicinet.com\/i\/wp-json\/wp\/v2\/posts\/203522\/revisions"}],"wp:attachment":[{"href":"http:\/\/healthmedicinet.com\/i\/wp-json\/wp\/v2\/media?parent=203522"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/healthmedicinet.com\/i\/wp-json\/wp\/v2\/categories?post=203522"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/healthmedicinet.com\/i\/wp-json\/wp\/v2\/tags?post=203522"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}